Latest news with #NMEs
Business Wire
05-05-2025
- Business
- Business Wire
Datavant and Boehringer Ingelheim Expand Partnership to Fuel Scalable Real-World Evidence Infrastructure
NEW YORK--(BUSINESS WIRE)-- Datavant, the leading health data platform company, today announced an expanded collaboration with Boehringer Ingelheim to support the pharmaceutical company's growing real-world evidence (RWE) initiatives. Through this partnership, Boehringer Ingelheim will leverage Datavant's privacy-preserving tokenization and data connectivity technologies to enhance clinical development and launch strategies across 75 additional clinical trials and multiple new molecular entities (NMEs). By leveraging Datavant Connect, powered by AWS Clean Rooms, Boehringer Ingelheim will be able to efficiently explore and assess third-party data sources without moving or sharing underlying data—streamlining data discovery, transformation, and linkage. This collaboration underscores the critical role of secure, connected data in driving more comprehensive insights into the patient journey. By leveraging Datavant Connect powered by AWS Clean Rooms, Boehringer Ingelheim will be able to efficiently explore and assess third-party data sources without moving or sharing underlying data—streamlining data discovery, transformation, and linkage within its own secure research environment. Arnaub Chatterjee, GM and President, Life Sciences, Ecosystem and Public Sector at Datavant, highlighted the transformative impact of the collaboration, "We are honored to support Boehringer Ingelheim in revolutionizing patient care through a pioneering data strategy. By enabling secure and efficient data linkage at scale, Boehringer Ingelheim is setting a new benchmark for medical research. This partnership exemplifies how technology can reshape healthcare and improve patient outcomes." By implementing Datavant's technology across a broad portfolio of trials and launches, Boehringer Ingelheim aims to accelerate the integration of real-world data into drug development, enabling more precise insights into treatment effectiveness, economic impact, and long-term health outcomes. Paul Petraro, Executive Director and Head of the Real World Evidence Analytics Center of Excellence at Boehringer Ingelheim, emphasized the significance of this initiative. "Our investment in real-world data underscores Boehringer Ingelheim's commitment to using cutting-edge technologies to advance medical research. By expanding this approach across more trials and commercial launches, we are positioned to drive more personalized and cost-effective treatments, ultimately transforming patient care," said Petraro. To ensure seamless integration with Boehringer Ingelheim's existing research infrastructure, teams will implement tokenization in a phased rollout. The collaboration aims to establish a robust framework to guide future studies and demonstrate the value to industry peers seeking to adopt a real-world evidence strategy based in cloud-first tokenization and data discovery. About Datavant Datavant is a health data platform company. We make the world's health data secure, accessible, and actionable. Datavant drives data connectivity into action by offering a proprietary platform and network that deliver critical solutions across the healthcare ecosystem. Datavant enables more than 60 million healthcare records to move between thousands of organizations, more than 70,000 hospitals and clinics, 75% of the 100 largest health systems, and an ecosystem of 300+ real-world data partners. To learn more about Datavant, visit About Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Discover more at
Yahoo
13-02-2025
- Business
- Yahoo
Computational Biology Market to Generate $9.52 Billion in Revenues in 2025; Forecast to Reach $22.47 Billion by 2029 - Analysis of the Key Drivers, Top Segments, Regional Shifts, Leading Players & More
Certara L.P., Chemical Computing Group, Compugen, Genedata AG, and Insilico Biotechnology AG Lead the Industry Computational Biology Market Dublin, Feb. 13, 2025 (GLOBE NEWSWIRE) -- The "Computational Biology Market Report 2025" has been added to computational biology market size has grown rapidly in recent years. It will grow from $8.09 billion in 2024 to $9.52 billion in 2025 at a compound annual growth rate (CAGR) of 17.6%. The growth in the historic period can be attributed to multi-omics integration, personalized medicine and precision healthcare, genomic sequencing revolution, handling biological big data. The computational biology market size is expected to see exponential growth in the next few years. It will grow to $22.47 billion in 2029 at a compound annual growth rate (CAGR) of 23.9%. The growth in the forecast period can be attributed to cloud computing and high-performance computing (HPC), quantitative and predictive biology adoption, collaborative interdisciplinary research, advancements in bioinformatics and computational tools. Major trends in the forecast period include advancements in data science and bioinformatics, genomic sequencing technologies, machine learning and ai in bioinformatics, drug discovery and development, personalized medicine and precision funding has been the major driver in the computational biology market. For instance, in April 2023, according to National Cancer Institute (NCI), a US-based government agency, in the fiscal year 2021, the NCI had a total budget of $6. 4 billion, which included $195 million in funding from the CURES Act. This represented a 1.6% increase, equivalent to $99. 3 million, compared to the preceding fiscal year. Therefore, government funding is driving the computational biology market increasing demand for personalized medicine is expected to propel the growth of computational biology going forward. For instance, in 2022, according to the Personalized Medicine Coalition, a US-based professional membership organization, the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs) in 2022. Out of the 35 therapeutic NMEs, approximately 34%, which amounts to 12 of them, are classified as personalized medicines by the Personalized Medicine Coalition (PMC). Therefore, the increasing demand for personalized medicine is driving the growth of the computational biology companies operating in the computational biology market are developing new solutions for proteomics research to gain a competitive edge in the market. For instance, in May 2023, Biognosys AG, a Switzerland-based biotechnology company launched Spectronaut 18 and unveiled significant scientific and technological enhancements for its exclusive proteomics research software and offerings. Spectronaut 18 offers high throughput and efficiency in data-independent acquisition (DIA) proteomics analysis. The company's TrueDiscovery platform accelerates biomarker discovery in fields like oncology and neuroscience by providing unparalleled depth and sensitivity in proteomics. TrueTarget enables high-resolution drug target identification and deconvolution, and Biognosys' iRT Kit, recommended for real-time system suitability monitoring, is now supported in combination with Bruker ProteoScape companies operating in the computational biology market are developing advanced biosimulation solutions to gain a competitive edge in the market. For instance, in June 2022, Certara, a US-based software development company launched new versions of its Immunogenicity (IG), Immuno-oncology (IO), and Vaccine Simulators to enhance the predictability of novel biologic therapies in drug development. These simulators are built on quantitative systems pharmacology (QSP) and use computational modeling and experimental data to understand drug interactions with biological systems and disease processes. They assist in creating virtual patients, conducting computer-based trials, and predicting drug behavior in patients, streamlining the drug development process and minimizing risks. Certara's IG Simulator assesses immunogenicity in various biologic therapies, the IO Simulator optimizes cancer therapy combinations, and the Vaccine Simulator determines vaccine dosing strategies. North America was the largest region in the computational biology market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the computational biology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the computational biology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain. Report Scope Markets Covered:1) By Services: In-house; Contract2) By Tools: Databases; Infrastructure (Hardware); Analysis Software and Services3) By Application: Cellular and Biological Simulation; Drug Discovery and Disease Modelling; Clinical Trials4) By End Users: Research; Pharmaceutical Industry; Commercial ApplicationsSubsegments:1) By In-house: Data Analysis; Software Development; Research And Development2) By Contract: Outsourced Bioinformatics; Collaborative Research; Data Management ServicesKey Companies Profiled: Certara L.P.; Chemical Computing Group Inc.; Compugen Ltd.; Genedata AG; Insilico Biotechnology AGTime Series: Five years historic and ten years Ratios of market size and growth to related markets, GDP proportions, expenditure per Segmentation: Country and regional historic and forecast data, market share of competitors, market Attributes Report Attribute Details No. of Pages 200 Forecast Period 2025-2029 Estimated Market Value (USD) in 2025 $9.52 Billion Forecasted Market Value (USD) by 2029 $22.47 Billion Compound Annual Growth Rate 23.9% Regions Covered Global Companies Featured in this Computational Biology Market Report Certara L.P. Chemical Computing Group Inc. Compugen Ltd. Genedata AG Insilico Biotechnology AG Dassault Systemes SE Instem PLC Rosa & Co. LLC Simulation Plus Inc. Nimbus Discovery LLC Rhenovia Pharma SAS Leadscope Inc. DNAnexus Altaris Capital Partner Genialis Inc. Inari Agriculture Inc. BC Platforms Ventus Therapeutics Monte Rosa Therapeutics Schrodinger Inc. Strand Life Sciences Entos Pharmaceuticals Numerate Inc. Insitro Recursion Pharmaceuticals Atomwise Relay Therapeutics Exscientia For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Computational Biology Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
